New pill aims to stop lung cancer return after surgery
NCT ID NCT07330076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests iruplinalkib tablets as a daily treatment after surgery for people with stage IA ALK-positive non-small cell lung cancer who have high-risk factors. The goal is to see if the drug can prevent the cancer from coming back. About 28 participants will take the pill for up to 2 years, and researchers will track how many remain cancer-free after 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iruplinalkib tablets
- What this could lead to
- If successful, this could provide a new treatment option to reduce the risk of cancer returning after surgery for early-stage ALK-positive lung cancer.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Can extended poziotinib use keep cancer in check?
- Can zapping tumors before surgery boost lung cancer treatment?
- Can a Two-Pronged antibody boost Chemo's power against lung cancer?